Mersana Therapeutics Stock Price, News & Analysis (NASDAQ:MRSN)

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Mersana Therapeutics Inc (NASDAQ:MRSN) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.02. The firm earned $0.20 million during the quarter, compared to analysts' expectations of $1.08 million. Mersana Therapeutics had a negative net margin of 77.78% and a negative return on equity of 51.13%. View Mersana Therapeutics' Earnings History.

Mersana Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Mersana Therapeutics.

5 equities research analysts have issued 12 month price objectives for Mersana Therapeutics' stock. Their forecasts range from $12.00 to $14.00. On average, they expect Mersana Therapeutics' share price to reach $13.00 in the next twelve months. This suggests a possible upside of 697.5% from the stock's current price. View Analyst Price Targets for Mersana Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mersana Therapeutics.

News headlines about MRSN stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Mersana Therapeutics earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Mersana Therapeutics.

Mersana Therapeutics saw a decrease in short interest in September. As of September 30th, there was short interest totalling 632,700 shares, a decrease of 9.3% from the August 30th total of 697,900 shares. Based on an average trading volume of 239,800 shares, the days-to-cover ratio is presently 2.6 days. Currently, 1.8% of the company's stock are sold short. View Mersana Therapeutics' Current Options Chain.

Some companies that are related to Mersana Therapeutics include OptiNose (OPTN), Atreca (BCEL), Rigel Pharmaceuticals (RIGL), Ardelyx (ARDX), Geron (GERN), Karuna Therapeutics (KRTX), Kindred Biosciences (KIN), Dynavax Technologies (DVAX), BIOFRONTERA AG/ADR (BFRA), Puma Biotechnology (PBYI), resTORbio (TORC), Recro Pharma (REPH), Constellation Pharmaceuticals (CNST), Cyclerion Therapeutics (CYCN) and Molecular Templates (MTEM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include Dynavax Technologies (DVAX), Eyepoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Coherus Biosciences (CHRS), Clearside Biomedical (CLSD), Exelixis (EXEL), ImmunoGen (IMGN), Immunomedics (IMMU), Kala Pharmaceuticals (KALA) and Madrigal Pharmaceuticals (MDGL).

(MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include NEA Management Company LLC (25.02%). Company insiders that own Mersana Therapeutics stock include Enterprise Associates 14 New and Timothy B Lowinger. View Institutional Ownership Trends for Mersana Therapeutics.

MRSN stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC. View Insider Buying and Selling for Mersana Therapeutics.

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MRSN stock can currently be purchased for approximately $1.63.

Mersana Therapeutics has a market capitalization of $77.93 million and generates $10.59 million in revenue each year. The company earns $-64,260,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe.View Additional Information About Mersana Therapeutics.

The official website for Mersana Therapeutics is http://www.mersana.com/.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]